Clinical Trials

Prostatic Neoplasms

NCT04073602 2023-12-18

A Study of RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial Cancer

19 enrolled

Carcinoma, Transitional Cell

NCT03809013 2023-11-27

A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer

64 enrolled

Carcinoma, Transitional Cell

NCT05140512 2023-05-16

Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®

23 enrolled

Prostatic Neoplasms

NCT05856630 2023-05-12

Pharmacokinetics Pharmacodynamics and Safety of LY01022 in Patients With Prostate Cancer Compared With Zoladex® 10.8mg

Phase 1 Unknown

24 enrolled

Prostatic Neoplasms

NCT03709550 2022-10-05

Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer

Phase 1/2 Withdrawn

Prostatic Neoplasms

NCT05488353 2022-08-04

A Clinical Study of Disitamab Vedotin for Injection Combined With Penpulimab Injection in Neoadjuvant Therapy for Patients With HER2-expressing Cisplatin-intolerant cT2-T4aNxM0 Bladder Urothelial Carcinoma

Phase 4 Unknown

48 enrolled

Urinary Bladder Neoplasms

NCT04563936 2021-08-26

Efficacy and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®

Phase 3 Completed

290 enrolled

Prostatic Neoplasms

NCT04568304 2020-09-29

A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma

Phase 3 Unknown

364 enrolled

Carcinoma, Transitional Cell

NCT04272645 2020-07-15

Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer

Phase 2 Withdrawn

Prostatic Neoplasms

NCT02223052 2020-05-12

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

BreastCNSDermatologicGenitourinaryGynecologicHead & NeckLymphoidMyeloidOther hematologic neoplasmPlasma cellSarcomaThoracic

89 enrolled

Urinary Bladder Neoplasms, Bone Neoplasms, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Glioblastoma, Hodgkin Disease, Kidney Neoplasms, Leukemia, Lung Neoplasms, Lymphoma, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Osteosarcoma, Skin Neoplasms, Testicular Neoplasms, Thyroid Neoplasms, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Small Cell Lung Carcinoma

NCT02647983 2020-01-22

Multiparametric MRI for Prostate Cancer Localization and Characterization Using Hyperpolarized Pyruvate (13C) Injection

Phase 1 Withdrawn

Prostatic Neoplasms

NCT03507166 2019-08-21

A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer

43 enrolled

Carcinoma, Transitional Cell

NCT02238366 2019-07-25

CHRONOS3

Completed

368 enrolled

CNSGastrointestinalGenitourinary

Prostatic Neoplasms

NCT02584400 2019-03-08

HX4 SD

Phase 2 Terminated

1 enrolled

Hypoxia, Brain Neoplasms, Esophageal Neoplasms, Neoplasm Metastasis, Prostatic Neoplasms, Rectal Neoplasms

NCT01993160 2017-01-13

18F-FCH (Fluorocholine)-PET/MR in Staging of High-Risk Prostate Cancer

Phase NA Completed

50 enrolled

Prostatic Neoplasms

NCT01481441 2016-07-06

AMC_2011_190

Phase NA Terminated

208 enrolled

Prostatic Neoplasms

NCT00667537 2015-12-14

PK in Pts With HRPC & Skeletal Metastes

6 enrolled

Prostatic Neoplasms

NCT01229618 2015-10-05

Hyperpolarized Pyruvate Injection in Subjects With Prostate Cancer

31 enrolled

Prostatic Neoplasms

NCT02208583 2014-08-05

Molecular Phenotype Changes and Personalized Treatment for CRPC

Phase NA Unknown

150 enrolled

Hormone Refractory Prostate Cancer

NCT00918281 2014-06-09

Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection